NIH ‘very concerned’ about serious side effect in AstraZeneca's PhIII Covid-19 trial
The FDA is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
